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ORIGINAL ARTICLE
Ulcerated lesions as a risk factor for Henoch-Schonlein 
purpura nephritis 
Ramon Ruben Bondin, Charles Joseph Borg, Victor Grech, Valerie Said Conti 
OBJECTIVE   
To determine the correlation between the severity of Henoch-
Schonlein purpura skin manifestations and development of nephritis 
and to characterise the disease within the Maltese paediatric 
population. 
DESIGN      
A retrospective analysis of the 96 cases diagnosed with Henoch-
Schonlein purpura at Mater Dei Hospital between January 2008 and 
January 2016. Clinical notes were reviewed and anonymised data   
regarding the presentation, progression and follow-up of these cases 
was entered into a database. 
RESULTS        
96 cases met the inclusion criteria with a male to female ratio of 
1.35:1 and with a mean age at presentation of 6.4 years (interquartile 
range 3.5 years). 99% had the typical rash at presentation with 75% 
having other associated clinical findings. Renal involvement was 
found in 36.5%:  isolated proteinuria in 19.8%, isolated haematuria in 
13.5%, haematuria, proteinuria and hypertension in 3.1% and 
nephrotic range proteinuria in 2% of cases. A severe rash at 
presentation was shown to be a prognostic indicator for renal 
involvement. 
CONCLUSION   
Henoch-Schonlein purpura in the Maltese paediatric population is 
similar in incidence to that quoted in the literature. The majority of 
cases are uncomplicated and the outcome is frequently favourable. 
The presence of a severe rash at presentation significantly increases 
the risk of renal involvement and long term complications.  
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INTRODUCTION 
Henoch-Schonlein Purpura (HSP) is the 
commonest vasculitis in childhood with an 
incidence between 3-27 per 100,000 child 
population, with an increased prevalence in 
males.1-2 It commonly presents between four 
and six years of age and is usually a self-
limiting disease with rapid resolution of extra-
renal symptoms. The long term prognosis 
correlates with renal involvement which 
involves about a third of cases. Chronic renal 
disease is estimated to occur in 1.8% of 
children and 10.4% of adults.4 Reports have 
shown a difference in presentation between 
childhood-onset and adolescent-onset HSP, 
with the latter having increased incidence of 
musculoskeletal symptoms and a marginally 
increased risk of progression to end-stage 
kidney disease.3 Korean and Japanese 
individuals also seem to have a higher 
prevalence of HSP as compared to other 
races.4 There are a number of rare 
complications that can be associated with HSP 
including orchitis, cerebral and cerebellar 
haemorrhage and pulmonary haemorrhage.  
Microscopically, the condition is characterised 
by the deposition of IgA immune complexes in 
the organ vasculature, hence its new 
nomenclature in the Chapel Hill classification, 
IgA vasculitis.4,5,6 Common viral infections 
often precede the condition as demonstrated 
by a higher incidence in the winter months. 
Predisposed individuals have abnormal 
glycosylation sites on IgA1 antibodies. Viral 
upper respiratory tract infections and 
gastrointestinal infections lead to increased 
production of these abnormal IgA1 antibodies 
and these are recognised by circulating anti-
glycan antibodies, leading to the formation of 
the circulating immune complexes with 
deposition in the organ vasculature.7 
Laboratory tests at presentation commonly 
show raised inflammatory markers and IgA 
levels and a variable degree of haematuria 
and/or proteinuria.8  
PATIENTS  AND METHOD 
The clinical notes of all patients aged less than 
16 years (otherwise passed to adults) admitted 
with HSP to Mater Dei Hospital between 
January 2008 and January 2016 were 
reviewed. Data included demographics, clinical 
findings at presentation, laboratory test 
results and out-patient follow-up findings. All 
data was anonymised in a database.  
We graded the severity of the rash as either 
mild, that is, a fine purpuric rash (figure 1), or 
severe, that is, palpable purpura with or 
without ulcerated lesions (figures 2 and 3). 
Figure 1  Showing mild purpura 
 
 
 
 
 
 
 
 
 
Blood tests were interpreted according to 
normal ranges for the patient’s age and sex. 
HSP nephritis was monitored using urine 
dipstick and formal urinalysis and microscopy.  
Haematuria was defined as 1+ to 3+ on dipstick 
whilst proteinuria was defined as 1+ to 3+ or 
greater than 150mg/L on dipstick on three 
consecutive days. Proteinuria was quantified 
using the urine albumin: urine creatinine ratio. 
Nephrotic range proteinuria was defined as a 
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24hr urine protein of more than 40mg/m2/hr 
whilst nephritic-nephrotic syndrome was 
defined as more than 200 red blood cells on 
urine analysis and 24hr urine protein of more 
than 40mg/m2/hr and the presence of 
hypertension and/or biochemical findings of 
renal dysfunction. Blood pressure values were 
compared to age, sex and height-matched 
percentile values and hypertension was 
considered if the measured systolic and 
diastolic values exceeded the 95th percentile 
according to the Clinical Practice Guideline for 
Screening and Management of High Blood 
Pressure in Children and 
Adolescents.15Recurrence of HSP was 
considered if a patient who was symptom-free 
for at least a month presented with fresh signs 
and/or symptoms related to HSP.  
Figure 2  Showing more severe palpable 
purpura 
 
 
 
 
 
 
 
Figure 3  showing severe purpura with 
blistering and ulcerated lesions 
 
Statistical analyses were performed using 
Microsoft Excel® 2010. Fisher Exact test was 
used to study the relationship between the 
severity of the skin rash and the presence of 
HSP nephritis. 
RESULTS 
Findings at presentation 
96 children met the inclusion criteria. The male 
to female ratio was 1.35:1 with a mean age of 
6.4 years (interquartile range 3.5 years). 65 
cases (67.7%) presented in the months 
between September and March. A preceding 
infection, a mean of 2.8 weeks previously, was 
noted in 85 cases (88.5%), the majority being 
upper respiratory tract infections (82%).Table 
1 summarises the clinical findings at first 
presentation.  
95 children (99%) presented with the typical 
purpuric rash; one child presented with 
abdominal pain first, with the rash appearing 
within 3 days. Most children had a fine purpuric 
rash involving the lower limbs. 7 children 
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(7.3%) presented with palpable purpura whilst 
another 7 children (7.3%) had ulcerated 
lesions. The mean age of children presenting 
with mild purpura was 6.9 ± 2.3 years whilst the 
mean age of children presenting with severe 
purpura was 5.4 ±1.38 years p=0.0202 (CI 
0.2392 - 2.76). 
35 children (36.5%) had evidence of renal 
involvement within the first week of 
presentation: 19 (19.8%) had proteinuria and 
13 (13.5%) had haematuria. Three children 
(3.1%) had a combination of haematuria ± 
proteinuria and hypertension at presentation. 
The clinical findings of the latter are shown in 
table 2. 
 
 
Clinical Signs And Symptoms At First Presentation  No. Of Cases 
Percentage of 
Total (%) 
          
Abdominal Pain     1 1 
Typical Purpuric Rash     95 99 
        
Type of Rash: Fine purpuric Rash   82 85.4 
  Palpable Purpura   7 7.3 
  Ulcerated Purpuric Lesions   7 7.3 
        
Rash distribution: Mainly Involving Lower Limbs   75 79 
  
Mainly Involving Upper and Lower 
Limbs   13 13.6 
  Rash Generally Distributed   7 7.4 
        
Associated Clinical Findings     72 75 
  Joint Pains and Swelling   54 56.3 
  Gastro-intestinal Symptoms   47 48.9 
  Abdominal Pain   39 40.6 
  Nausea and/or vomiting   4 4.2 
  Colitis and Intussusception  1 1 
  Evidence of Renal Involvement   35 36.5 
  Proteinuria only   19 19.8 
  Haematuria only   13 13.5 
  
Proteinuria, Haematuria and 
Hypertension   3 3.1 
Table 1   Summary of the signs and symptoms noted at first presentation 
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One child with nephritic-nephrotic 
presentation underwent a renal biopsy. The 
histological findings were consistent with IgA 
nephropathy. 
Two patients experienced serious medical 
complications. One child developed nephrotic 
syndrome with heavy proteinuria and 
hypoalbuminaemia resulting in significant fluid 
overload with pulmonary oedema. Another 
patient developed severe abdominal pain and 
was found to have intussusception, requiring 
air reduction. Other rare complications such as 
orchitis, cerebral and cerebellar haemorrhage 
and pulmonary haemorrhage were not 
encountered in our study. 
FINDINGS ON FOLLOW-UP 
93 children (96.9%) were followed-up in clinic 
at least once; the rest were lost to follow-up. 
84 cases (87.5%) showed complete resolution 
of signs and symptoms within 2 months from 
presentation and were subsequently 
discharged by 6 months from the first 
presentation. Rash recurrence occurred in 12 
cases (12.5%), with the majority (75%) of these 
recurrences occurring within 2 months from 
the initial presentation with no easily 
recognisable trigger.  
Interestingly, two of the three patients 
presenting with nephritis and hypertension 
(Table 2) had a recurrence of HSP and this was 
Table 2   Summary of the signs and symptoms noted at first presentation 
 Findings at presentation 
BP 
(P95 systolic 
and diastolic 
value) 
24hr Urine 
Protein 
g/day 
UAUC 
mg/g 
Serum 
albumin 
g/L 
eGFR 
mL/min/
1.72m2 
Case 1 
Male  
5yr old 
• Palpable purpura 
over lower limbs 
and abdomen 
• Ankle swelling and 
pain. 
• No fluid overload 
107/85mmHg 
 
(BP 108/68) 
0.638 6690 24 118 
Case 2  
Male 
10yr old 
• Rash involving 
lower limbs and 
buttocks 
• No abdominal pain 
• No fluid overload 
112/72mmHg 
 
(BP 115/75) 
 0.426mg 775 38 158 
Case 3 
Female 
5yr old 
• Difficulty walking 
• Abdominal pain, 
vomiting 
• Rash both lower 
and upper limbs on 
day 3 
• Rash blistered and 
ulcerated by day 6. 
• Small amount of 
free fluid in RIF on 
ultrasound 
128/82mmHg 
 
(BP 106/68) 
 not 
measured 
2.5 44.7 106 
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associated with worsening of the kidney 
disease, as demonstrated in Table 3.  
Table 4 and Table 5 represent a summary of 
the clinical findings that were observed in this 
study with Table 5 comparing the severity of 
the rash compared to the renal and extra-renal 
involvement.  
Fisher Exact Test was used to correlate the 
severity of the rash with the incidence of renal 
involvement and this revealed a statistically 
significant association between the two; 
p=0.008, odds ratio is 0.21 (0.06-0.72) and a 
relative risk of 0.48 (0.39-0.59) with a severe, 
ulcerating rash more likely to be associated 
with nephritis. (Table 5) 
 
 
Table 3    Clinico-pathological findings during the recurrent episodes of HSP 
 Findings during first recurrence 
Findings during subsequent 
recurrences 
Kidney biopsy 
Case 1 
Male  
5yr old 
2 recurrences 
• 5 months from first 
presentation 
• Palpable purpura over 
limbs and trunk, abdominal 
pain, scrotal swelling 
• BP 115/70 
• Prednisolone 4mg/kg daily 
for 4 weeks 
• 6 m from first presentation 
• Developed generalised 
oedema with pulmonary 
oedema and weight gain of 
5.3 Kg  
• Serum albumin 16.8g/L  
• UAUC increased to 6690mg/g 
• Introduced mycophenolate 
mofetil to high dose oral 
steroids 
IgA 
nephropathy  
Case 2  
Male 
10yr old 
1 recurrence 
• 2 months from first 
presentation 
• Urine dipstick 4+ protein 
and 4+ blood 
• 24 hr urine protein 
1.632g/d 
• BP 110/80mmHg 
• Started on angiotensin 
converting enzyme 
inhibitor (ACEi) 
• No further recurrences 
• Persistent proteinuria. No 
haematuria 
• 24hr urine protein 0.6 – 
0.7g/d  
• Receiving ACEi 
Not 
performed 
Case 3 
Female 
5yr old 
3 recurrences 
• 1 month from first 
presentation 
• Serum albumin 35g/L 
• UAUC 1480-1650mg/g 
• Hypertensive on ACEi 
• Introduced furosemide 
• Second recurrence 7 months 
from first presentation, 
possibly precipitated by a 
viral URTI 
• Persistent haematuria 2+ and 
proteinuria 3+ 
• UAUC 280-300mg/g 
• Introduced ACEi 
• 3rd recurrence 5.5yrs from 
first presentation 
• Presented with abdominal 
pain and purpuric rash 
involving lower limbs 
• 24hr urine protein 0.3g/d 
• BP 120/80mmHg (P90 
115/74) 
Not 
performed 
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In children presenting with proteinuria and/or 
haematuria there was complete resolution in 
47% of cases by 1 year and in 80% of cases by 
three years. Two cases developed proteinuria 
during follow-up rather than during the initial 
presentation with HSP. These occurred within 
the first four months from presentation and 
both required a follow-up of over one year for 
the proteinuria to disappear. 
 
DISCUSSION 
This is the first study that characterises the 
course of HSP in the Maltese paediatric 
population. The prevalence of HSP is higher in 
males with a male to female ratio of 1.35:1 
which is slightly less than that of 1.8:1 quoted 
in the literature.9 The mean age at 
presentation is similar to that quoted in the 
literature. The presenting feature of the 
disease is the ubiquitous rash with a variable 
Table 4     Summary of clinical manifestations of HSP 
HSP rash with involvement of: 
number 
of cases 
Fine non-
palpable 
purpura 
Palpable 
Purpura 
Ulcerated/ 
blistering 
purpuric 
lesions 
No other system 24 23 1 0 
Renal system only 4 2 2 0 
Renal and musculoskeletal only 16 12 1 3 
Renal and gastrointestinal system 
only 12 11 0 1 
Renal, musculoskeletal and gastro-
intestinal system 6 3 1 2 
Gastro-intestinal involvement only 2 0 1 1 
Gastro-intestinal and musculoskeletal 
system only 27 26 1 0 
Musculoskeletal/joints only 5 5 0 0 
Table 5     Comparison of the renal and non-renal manifestations against the severity 
   of the purpuric rash. 
 Non-renal involvement Renal involvement 
Mild purpura 54 28 
Severe Purpura 4 10 
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distribution and severity. The majority of the 
cases (79%) had the typical HSP rash 
presenting in the lower limbs with only a 
minority having the upper limbs also affected, 
or having a generalised rash. Childhood HSP 
does tend to affect the lower limbs whilst 
adolescent or adult onset HSP tends to affect 
mainly the upper extremities more commonly 
for reasons unknown.3  
Gastrointestinal involvement, joint 
involvement and age over 8 years have been 
shown to be independent risk factors for 
developing nephritis, increasing the risk 2-3 
fold.3,16 From our study, it is apparent that the 
severity of the skin rash is significantly 
associated with the development of nephritis 
(p=0.008). We also noted that younger children 
developed a more severe rash than their older 
counterparts (p=0.02). 
HSP associated nephritis (HSN) occurs in about 
a third of cases and determines the long-term 
prognosis. At presentation, 36% of cases in our 
study showed a degree of proteinuria and/or 
haematuria to suggest HSN and this persisted 
for at least 1 year of follow-up in half of the 
cases. A minority (3.1%) had proteinuria, 
haematuria and hypertension and two cases 
required immunosuppressive medication and 
ACE inhibition. The importance of monitoring 
the urine for proteinuria/haematuria and the 
blood pressure cannot be overemphasised and 
recommendations for long-term follow-up 
have been put forward. HSN tends to develop 
within the first 4 weeks after the onset of HSP 
and at most, within the first 3 months.16The 
presence of nephritis at presentation 
increases the likelihood of developing chronic 
renal disease.16 A kidney biopsy may be 
warranted in selected cases  together with 
consideration of  immune suppressive 
therapy.11 The use of ACE inhibitors and 
control of hypertension has been shown to be 
renoprotective.12-13 The use of corticosteroids 
and immunosuppressive therapy is mainly 
limited to cases with severe nephritis and 
should be considered after kidney biopsy and 
consideration of the updated Oxford 
classification score which is useful in predicting 
long-term outcomes of HSP nephritis.13-14 
HSP followed a mild course in the majority of 
the cases with complete recovery on follow-
up. Most of these recoveries occurred in the 
first 3 months with the rash typically fading 
within the first 50 days. The recurrence rate 
was 12.5% and occurred within the first 2 
months from the initial presentation but could 
take up to 5 months. No obvious trigger was 
identifiable for the recurrence in the majority 
of cases. 
CONCLUSIONS 
This study demonstrated that HSP in the 
Maltese paediatric population has similar 
presenting and long term clinical 
characteristics to that of other European 
populations.9,10 A limitation of the study was 
that some mild cases of HSP presentations or 
relapses may have been treated in the 
community and would not have been included. 
Risk factors for developing nephritis are 
described as an older age at presentation 
(greater than 8 years), the presence of 
abdominal pain and recurrence of HSP. We 
have shown that increasing severity of the 
purpuric rash at presentation can also increase 
the likelihood of developing nephritis.  
In most cases of HSP, the prognosis for 
complete remission is good and only a minority 
develop persistent renal disease requiring 
specialist management.  
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